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Abstract 19 
There is a complex interplay between mobility and cognition in older adults. We have 20 
previously shown that a high DHA multi-nutrient supplement improves habitual walking 21 
speed, verbal memory, and psychomotor response latency in older women. Exercise also 22 
improves mobility and cognition in older adults, and omega-3 fatty acids and exercise share a 23 
range of overlapping biological effects. This study examined for the first time the effects of 24 
the high DHA multi-nutrient supplement and aerobic exercise on mobility and cognition in 25 
older women. Women (mean age 67 y, SD 8) were assigned to the following groups: multi-26 
nutrient (1 g DHA, 160 mg EPA, 240 mg Ginkgo biloba, 60 mg phosphatidylserine, 20 mg d-27 
 tocopherol, 1 mg folic acid, and 20 µg vitamin B12 per day, N=13), multi-nutrient and 28 
exercise (spin class twice per week, N=14), exercise and placebo (N=12), or placebo (N=12). 29 
The multi-nutrient was given for 24 weeks, and exercise for 12 weeks. Trial registration: 30 
NCT03228550. No treatment effects were observed for the primary outcome, habitual 31 
walking speed. Improvements in verbal memory and executive function were seen for all 32 
treatments groups versus placebo (all, p<0.05). Significant improvements in self-reported 33 
emotional wellbeing were seen with multi-nutrient and exercise groups versus placebo 34 
(p=0.03). The results suggest that the high DHA multi-nutrient supplement produces similar 35 
improvements in cognitive function to aerobic exercise, offering the intriguing prospect that 36 
supplementation may be able to mitigate some of the effects of low physical activity on 37 
cognitive function in the elderly.  38 
 39 
 40 
 41 
 42 
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Introduction  43 
Ageing is associated with a progressive decline in both cognitive and physical function, 44 
which can lead to a number of age-related health conditions including frailty and dementia 
(1)
. 45 
Walking is a complex task with a significant cognitive aspect, and changes in several gait 46 
parameters including speed often coexist with or precede the onset of cognitive decline in 47 
older adults 
(2)
. Gait speed is a clinically relevant marker in older adults, due to strong 48 
associations with physical functioning and disability 
(3)
. Previous work in our laboratory 49 
suggests a high docosahexaenoic acid (DHA) multi-nutrient supplement providing the 50 
omega-3 polyunsaturated fatty acids (PUFAs), DHA and eicosapentaenoic acid (EPA), and 51 
supporting nutrients phosphatidylserine (PS), d- tocopherol, folic acid, vitamin B12, and 52 
Ginkgo biloba, improves cognition and mobility in older females 
(4)
.  53 
 54 
Providing omega-3 PUFAs in combination with other compounds indicated to support brain 55 
function may provide greater efficacy than if supplemented in isolation, although results are 56 
so far mixed. For example, the same multi-nutrient supplement as used in our previous and 57 
present studies did not improve cerebral hemodynamic or cognitive function in healthy older 58 
adults 
(5)
; however, the authors acknowledge that the cognitive tests were selected on the 59 
basis that they are able to activate the prefrontal cortex, and may not be sensitive to the 60 
components in the supplement. Similarly, an omega-3 PUFA multi-nutrient supplement 61 
showed no significant effects on a battery of cognitive tests of participants with prodromal 62 
Alzheimer’s disease, although improvements were seen in secondary outcomes of cognitive 63 
function and hippocampal atrophy 
(6)
.  64 
 65 
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Aerobic exercise has consistently been shown to improve both mobility and cognition in 66 
older adults 
(7)
. Omega-3 PUFAs and exercise share a range of overlapping biological effects, 67 
including enhancing neurogenesis, neural plasticity, and reducing inflammation 
(8, 9)
. Indeed, 68 
preliminary evidence suggests combining omega-3 PUFAs with exercise may provide 69 
additional benefit when compared to either approach alone. For example, omega-3 PUFA 70 
supplementation combined with twice weekly stationary cycle training and cognitive 71 
stimulation led to an enhanced reduction of brain atrophy in grey matter regions compared to 72 
supplementation 
(10)
. Similarly, combining omega-3 PUFA supplementation with resistance 73 
training in older females provided an additional benefit to muscle strength compared with the 74 
exercise alone 
(11)
. In addition, an omega-3 PUFA multi-nutrient supplement combined with 75 
exercise was recently shown to improve verbal recall and executive function in older men, 76 
more than supplementation alone 
(12)
. The mechanisms underpinning these interactions are 77 
currently unclear, as the studies were not been designed to elucidate these effects. However, 78 
decreasing  Hcy levels may be a potential factor, as omega-3 PUFAs regulate the expression 79 
of genes encoding enzymes involved in Hcy metabolism 
(13)
 and exercise decreases Hcy 80 
levels 
(14)
. 81 
 82 
The aim of this study is to further our initial observations and examine for the first time the 83 
effects of the multi-nutrient supplement and aerobic exercise on mobility and cognition in 84 
older women. The study was restricted to female participants to enable comparison with our 85 
previous work 
(4)
, and it has been suggested that the additive effects of combining exercise 86 
and omega-3 PUFA supplementation may be limited to women only 
(11)
. Women have also 87 
been shown to have a greater compliance to exercise interventions 
(15)
. Habitual gait speed 88 
was the primary outcome, with secondary outcomes related to mobility, cognition, and 89 
quality of life 
(16)
.   90 
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Methods  91 
The study is a randomised semi-blinded, placebo controlled trial in women aged 60 years and 92 
above with a factorial design. Detailed information of the study procedure has been 93 
previously published 
(17)
, in line with guidelines of the Template for Intervention Description 94 
and Replication 
(18)
. This study was conducted according to the guidelines laid down in the 95 
Declaration of Helsinki and all procedures involving human subjects/patients were approved 96 
by the Bournemouth University Science Technology and Health research ethics panel (Ethics 97 
ID 10788). Prior to data collection participants provided written informed consent. The trial 98 
was listed on www.clinicaltrials.gov (NCT03228550), and follows the Consolidated 99 
Standards of Reporting Trials (CONSORT) statement on randomised trials 
(19)
. All data was 100 
collected and analysed at Bournemouth University, U.K. 101 
 102 
Participants  103 
Females aged 60 years and above were recruited according to the following inclusion criteria: 104 
(1) able to walk at least 50 m unaided, (2) classified as non-frail or pre-frail 
(20)
, and (3) 105 
community dwelling. Exclusion criteria were: (1) vestibular impairments, (2) diagnosed 106 
neurological disorder, (3) cognitive impairment (Mini Mental Status Examination score <24), 107 
(4) lower limb surgery, (5) seafood allergy, (6) regular consumption of multivitamin or fish 108 
oil supplements within six months prior to baseline measurements, and (6) previously 109 
received advice from a health care professional not to undertake strenuous exercise. A 110 
stratified block randomisation design was followed based on frailty classification of non-frail 111 
or pre-frail, followed by permuted block randomisation. Participant demographics can be 112 
found in Table 1. For further information please refer to the published protocol 
(17)
.  113 
 114 
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Interventions 115 
Participants were allocated to one of four groups: multi-nutrient supplement and exercise 116 
(MS+EX), placebo supplement and exercise (P+EX), multi-nutrient supplement only (MS), 117 
or placebo supplement only (P). 118 
 119 
Dietary supplement  120 
Participants received four capsules per day of their respective dietary supplement for 24 121 
weeks. The daily dose from the active capsules contained 1000 mg DHA, 160 mg EPA, 20 122 
µg vitamin B12, 1 mg folic acid, 124 mg PS, 240 mg Ginkgo biloba standardized leaf extract, 123 
and 20 mg vitamin E. The placebo capsules contained an isocaloric oil blend typical of the 124 
U.K. diet including a small amount of fish oil. A small amount of fish oil was added to the 125 
placebo capsules to aid with participant blinding, which provided a daily dose of 21.6 mg 126 
EPA and 14.4 mg DHA, an amount unlikely to produce any therapeutic benefit 127 
(Supplementary Table 1). Participants were told to take their capsules with the largest meal of 128 
the day. The capsules were coded by the Principal Investigator (PI), who had no involvement 129 
in the data collection, and all subsequent operational oversight and interpretation of the data 130 
was undertaken with the PI blinded to specific participant codes. Compliance to the dietary 131 
supplement was measured by changes in whole-blood DHA levels compared to baseline, 132 
counting returned pills at 12 and 24 weeks, and exit questionnaire. Adverse events were 133 
monitored by subject self-reporting and exit questionnaire. 134 
 135 
Exercise  136 
The exercise intervention consisted of two group sessions per week on a Spinner Fit 137 
stationary bike. Classes lasted 30 min for the first six weeks and increased to 45 min for the 138 
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second six weeks, with five min warm up and cool down at 7-8 on the Borg scale of rate of 139 
perceived exertion. During the main body of the sessions participants maintained an intensity 140 
of 12-14 on the Borg scale. Compliance to the exercise intervention was monitored by 141 
recording attendances by each participant and calculated as the percentage of classes 142 
attended. 143 
Outcome measures   144 
The outcome measures were based on changes in mobility, cognitive function and health 145 
related quality of life, with the primary outcome measure change in habitual walking speed. 146 
Information on the age, Body Mass Index (BMI), verbal intelligence, and medication use 147 
were collected from each participant. Information on medications was self-reported, with 148 
both type and number of medications recorded. The National Adult Reading Test 149 
(NART) was used to assess verbal intelligence. All measurements were performed at baseline 150 
and end of the study.  151 
 152 
Mobility 153 
Participants were assessed under three gait conditions: habitual walking, fast walking, and 154 
dual task (DT) walking. During the DT participants were required to count backwards in 155 
integers of three from a randomly generated three digit number, and were not instructed to 156 
prioritise either walking or counting backwards during the task. Gait speed was measured 157 
using Opal inertial sensors and analysed using Mobility Lab™ software version 3.1 (APDM 158 
Inc, http://apdm.com). Sensors were placed over the shoes. Each tested condition was 159 
repeated five times and the mean value for each trial used for habitual and DT gait with the 160 
maximum gait speed value being used for fast walking. The five times sit to stand (5TSTS) 161 
test was used to assess dynamic balance and functional mobility.  162 
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 163 
Cognition 164 
A Stroop test was used to assess interference control using Open Sesame version 3.1.1. 165 
software 
(21)
. Participants were presented names of one of four colours: blue, red, green, and 166 
white, in four different font colours varying between these colours. Participants were required 167 
to identify the colour of the text. Interference control was defined as the difference between 168 
the mean time taken to respond to the congruent and non-congruent trials. Spatial memory 169 
was also assessed using Open Sesame software, based upon Nagamatsu and colleagues 
(22)
. 170 
Each trial comprised presentation of three dots at randomly allocated locations for 500 ms, 171 
followed by a fixation cross for three seconds. The test comprised presentation of a single red 172 
dot on the screen, either in the same location (match) or a different (non-match) location, and 173 
participants had to identify if the test dot was match or non-match. The Rey’s Auditory 174 
Verbal Learning Test (RAVLT) was used to assess verbal memory, where participants were 175 
required to recall a list of 15 pre-set words 
(23)
. The trail making task was used to assess 176 
executive function 
(24)
, where participants drew lines between targets on a piece of paper, as 177 
rapidly as possible, under four different conditions: (1) numbers condition (one to 49), (2) 178 
letters condition, (A to Z), (3) alternated numbers (one to 25) and letters (A to X), and (4) 179 
alternated letters (A to Y) and numbers (one to 24). Scores were recorded as the total number 180 
of correct connections. 181 
 182 
Health related quality of life 183 
The short form 36 questionnaire (SF-36) was used to asses health related quality of life 
(25)
.  184 
 185 
Biochemical measures 186 
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Biochemical measures were conducted to assess compliance to the supplementation and to 187 
better understand how changes may contribute towards any therapeutic effects on the 188 
measured outcomes.  Finger pin-prick blood samples were collected and total fatty acid 189 
content analysed, as described previously 
(26)
. Individual fatty acids were quantified using a 190 
gas chromatograph with flame ionisation detector (Agilent Technologies, U.S.A), and 191 
expressed as % of total fatty acids. A non-fasted venous blood sample was drawn to assess 192 
serum Hcy. Each sample was allowed to clot and immediately centrifuged at 2000 x g for 10 193 
min at 4⁰ C and serum extracted. Samples were stored at -80C and analysed within three 194 
months. Hcy levels were measured by competitive enzyme-linked immunosorbent assay 195 
(ELISA) (Cell Biolabs Inc.) according to manufacturer’s instructions. 196 
 197 
Diet and lifestyle  198 
Participants’ diet and lifestyle habits were monitored. Three day food diaries were used and 199 
results analysed using Nutritics dietary analysis software (www.nutritics.com). A validated 200 
food frequency questionnaire (FFQ) was used to quantify omega-3 PUFA intake 
(27)
. The 201 
community health activities program for seniors (CHAMPS) questionnaire was used to assess 202 
physical activity levels. These measures were taken  so that baseline diet and physical activity 203 
habits could be included as covariates and  to monitor whether there were any significant 204 
changes in diet and lifestyle during the course of the intervention period. 205 
 206 
Statistical analysis  207 
Statistical analyses were performed using IBM SPSS statistics version 21 (Chicago, USA). 208 
Sample size was determined based on the primary outcome of habitual walking speed. Using 209 
an effect size based on previously published values, minimally significant changes in gait 210 
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speed were 0.03 m/s and 0.05 m/s with substantial changes at 0.08 m/s 
(28)
. The sample size 211 
calculation was based on a difference of 0.08 m/sec with the level of variability set at 0.1 212 
based on our previous work 
(4)
 with a minimum sample size of 13 participants per group 213 
required to detect an effect size d of 0.5. In our original protocol a large effect size was 214 
suggested; however, this was subsequently changed to a medium effect size based on our 215 
previous pilot study 
(4, 17)
. Data were tested for normal distribution using Shapiro-Wilk test 216 
and Q-Q-plots and Levenes test of equality of error variances to check for assumptions of 217 
homogeneity. Correlations between mobility, cognitive function, and health related quality of 218 
life, exercise, circulating omega-3 PUFAs and Hcy were examined using partial correlations, 219 
controlling for age, BMI and dietary protein. For any variables that did not meet the 220 
assumptions of normality for partial correlations a syntax was used to produce a non-221 
parametric partial correlation. This method consisted of using the NONPAR CORR and 222 
/MATRIX OUT commands to produce a Spearman Rho matrix, which could then be read by 223 
the /MATRIX IN and PARTIAL CORR command whilst factoring in the appropriate 224 
covariates. For all correlation analysis a sample size of 46 was required to achieve a power of 225 
0.80 for a correlation coefficient of 0.40 and an α of 0.05 (29). Evidence suggests a non-linear 226 
relationship between Hcy and health of older adults 
(30)
, therefore non-parametric correlation 227 
analysis was performed. NART score was included as a covariate in preliminary analysis, but 228 
was excluded in final models.  229 
Baseline and 24 week results from the diet and physical activity assessments were compared 230 
within groups, using paired T-tests. A general linear model was used to compare the active 231 
intervention groups versus the placebo over time (from pre- to post-measurement) on changes 232 
on the dependent variables on an intention to treat basis. Effect size calculation (η² (Eta 233 
squared)) was performed. Demographic and health information, such as age, and BMI were 234 
included as covariates in the analysis if they were significantly correlated with the dependent 235 
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variable. The Benjamini-Hochberg procedure was used to decrease the false discovery rate 236 
and probability of type I errors, with a Q value of <0.25 accepted as significant, and all P 237 
values are expressed as raw values 
(31)
. Linear regression we used to identify whether a 238 
difference in whole-blood DHA was associated with a change in outcome score. All results 239 
are expressed as means (SD). Pre-trial registration plans dictated that a 2 x 2 ANOVA would 240 
be conducted to examine treatment effects, however due to the potential interaction between 241 
the supplementation and exercise independence of these variables could not be guaranteed, 242 
thus examining treatment effects based on the assigned groups was determined to be a more 243 
robust method. Correlation analysis was used to identify whether a difference in whole-blood 244 
DHA was associated with a change in outcome score. All results are expressed as means 245 
(SD). 246 
 247 
Results  248 
Participant flow is shown in Fig 1. The study had three separate intakes of participants, 249 
starting in March 2017, May 2017, and February 2018, with data collection taking place 250 
between March 2017 and January 2019. In total 60 participants were allocated to intervention 251 
groups and 51 completed the study. Analyses were conducted on all who completed the study 252 
with no exclusions irrespective of compliance or protocol violations. Participants who 253 
withdrew during the study were invited to attend follow up assessment; however, the 254 
invitations were declined. Role limitations due to physical health problems, role limitations 255 
due to emotional health problems, and social functioning from the SF-36 questionnaire 256 
showed clear signs of ceiling effects, therefore these were omitted from analysis. Hcy data 257 
was only available for 48 baseline values. Upon inspection four results of the baseline whole-258 
blood DHA levels were identified as unreliable and were subsequently excluded from the 259 
analysis.  260 
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 261 
The group baseline characteristics are shown in Table 1. There were no reported adverse 262 
effects in any group over the study. The multi-nutrient supplementation led to significant 263 
increases in DHA and EPA compared to baseline levels in the MS (28% and 190%, 264 
respectively) and MS+EX (43% and 140%, respectively) groups, and significant decreases in 265 
the omega-6 PUFA, arachidonic acid levels of -28% and -26%, respectively, all p < 0.05, 266 
Table 2. Compliance to the supplementation measured via changes in DHA and was 91% for 267 
MS+EX, and 80% for MS, 100% for P+EX and 100% for P, which was corroborated by 268 
capsule counting. Compliance to the exercise intervention was 55% for MS+EX and 56% for 269 
P+EX, which is consistent with other exercise intervention trials in a similar demographic (22). 270 
There were no significant changes in reported calorie, macronutrient or omega-3 PUFA 271 
intake between baseline and follow up, Table 2. Participants maintained their current use of 272 
medications and there were no reported changes health status throughout the duration of the 273 
study with the exception of two participants in the MS+EX who discontinued their use of 274 
analgesic and anti-inflammatory medications.  275 
 276 
Primary outcome measure 277 
There was a non-significant decrease of 0.8% in the mean habitual walking speed by the P 278 
group over the study; whereas, the other groups increased their mean walking speed by 0.05 279 
m/s (0.07 m/s) (4.0%) for the MS group, 0.03 m/s (0.09 m/s) (2.5%) for the P+EX group, and 280 
0.01 m/s (0.12 m/s) (0.8%) for the MS+EX group. However, these changes were not 281 
statistically significant for supplementation (p = 0.25), exercise (p = 0.50) or for the 282 
combined intervention (p = 0.79), Fig 2. 283 
 284 
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Secondary outcome measures 285 
The results for the effects of the interventions on mobility, cognition, and health related 286 
quality of life are summarised in Table 3. There was a significant effect on verbal memory 287 
compared with the P group, by the MS [F(1,46) = 7.59, p = 0.008, partial η2 0.144)], P+EX 288 
[F(1,46) = 7.70, p = 0.008, partial η2 0.144] and MS+EX interventions [F(1,46) = 15.82, p < 289 
0.001, partial η2 0.256], all with large effect sizes, Fig 3. Significant effects versus placebo 290 
were also observed for executive function for the MS [F(1,47) = 8.02, p = 0.007, partial η2 291 
0.146)], P+EX  [F(1,47) = 8.37, p = 0.006, partial η2 0.151)], and MS+EX groups [F(1,47) = 292 
8.60, p = 0.005, partial η2 0.155)] all with large effect sizes, Fig 4. The MS+EX group also 293 
reported significant improvements in emotional wellbeing, compared to the P group [F(1,47) 294 
= 8.07, p = 0.03, partial η2 0.146], with a large effect size. No significant treatment effects 295 
were observed for the other outcomes. 296 
 297 
Correlations of outcomes with DHA status and Serum Hcy 298 
Significant baseline relationships between DHA and DT gait speed r(53) = 0.32, p = 0.018, 299 
bodily pain r(51) = 0.35, p = 0.013 and emotional wellbeing r(51) = 0.30, p = 0.032 from the 300 
SF-36 questionnaire were identified. These relationships were moderate to weak in strength. 301 
There were no significant associations between DHA and any cognitive outcomes. Following 302 
the interventions there was a direct relationship between changes in verbal memory and DHA 303 
levels, r(18) = 0.66, p = 0.001, Fig 5, however no relationship was detected for changes in 304 
executive function. At baseline there were no significant associations between serum Hcy and 305 
any of the outcome measures (Supplementary Table 2). 306 
 307 
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Discussion  308 
The MOBILE study explores for the first time the effects of a high DHA multi-nutrient 309 
supplement and aerobic exercise on mobility and cognition in older women. Although the 310 
supplementation led to significant increases in DHA levels, there were no significant 311 
improvements in the primary outcome measure of habitual walking speed. However, 312 
significant improvements in verbal memory and executive function were seen following the 313 
interventions, with the improvements in verbal memory in direct relation to increases in 314 
whole-blood DHA levels. Furthermore, lower circulating DHA was associated with poorer 315 
DT performance, and measures of pain and emotional wellbeing at baseline.  316 
 317 
Significant improvements in habitual walking speed were previously shown by us following 318 
treatment with the same multi-nutrient supplement, reflecting clinically relevant 319 
improvements within a similar sample size 
(4)
. These improvements were driven by both 320 
improvements in the treatment group and decreases in the placebo group. However, in the 321 
present study although there were increases following the multi-nutrient supplementation of a 322 
similar magnitude to our previous study, the decline in the placebo group was much less than 323 
predicted, with a mean decline of 0.8%, as opposed to 2% in our previous study 
(32)
, which 324 
may reflect a high functioning nature of the participants. Indeed, the lack of improvement 325 
following the exercise intervention supports this hypothesis, as aerobic exercise has 326 
consistently been shown to improve walking speed 
(33, 34)
. Interestingly the effect size for the 327 
combined supplementation and exercise group was modest in comparison to each 328 
intervention on their own however this may be partly explained by the aforementioned 329 
participants who discontinued daily use of analgesic and anti-inflammatory for joint pain who 330 
both observed small declines in gait speed of 0.01 m/s. 331 
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The individual and combined interventions led to improvements in verbal memory, with the 332 
total recall across the trials representing eight to twelve more words remembered than the 333 
placebo group. These findings corroborate previous observations showing positive effects on 334 
verbal memory following treatment with the same multi-nutrient supplement 
(4)
. Similarly, 335 
the improvements following exercise are consistent with previous research 
(7)
. The individual 336 
and combined interventions also resulted in significantly improved executive function. The 337 
observation of exercise improving this cognitive domain is consistent with previous 338 
experimental work 
(7)
. There is currently no clear consensus in the literature as to whether the 339 
factors in the multi-nutrient supplement improve executive function in older adults. For 340 
example, 900 mg DHA for 24 weeks had no effect on executive function 
(35)
, whereas 1320 341 
mg EPA and 880 mg DHA for 26 weeks produced significant improvements 
(36)
. Similarly, 342 
although B vitamins 
(37)
 and Ginkgo biloba 
(38)
 do not appear to improve executive function, 343 
preliminary evidence suggests PS has some beneficial effects 
(39)
. A recent study suggested an 344 
omega-3 PUFA multi-nutrient supplement combined with exercise improves executive 345 
function in older men 
(12)
; however, as there was no exercise only control group the 346 
contribution of omega-3 PUFA multi-nutrient supplement to these effects cannot be 347 
identified. Indeed our analysis found no significant relationship between changes in blood 348 
level of DHA and the executive function suggesting that other factors may have contributed 349 
towards the change in this outcome. 350 
Due to the small sample size analysis to detect superiority of the active interventions over one 351 
another was not possible. It may be hypothesised that the effects of the multi-nutrient 352 
supplement and exercise operate via overlapping biological mechanisms. This includes 353 
decreasing inflammation, for example, interleukin 6 (IL-6) levels are linked to declines in 354 
verbal memory 
(40)
, and both omega-3 PUFAs and aerobic exercise have both been shown to 355 
decrease IL-6 levels 
(41)
. Alternatively, exercise and factors in the multi-nutrient supplement, 356 
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such as DHA and Ginkgo biloba increase brain-derived neurotrophic factor (BDNF) levels, 357 
which may contribute to enhancing synaptic plasticity and cognitive function 
(42-44)
. However, 358 
further work is needed to explore these potential mechanisms, if they mediate any of the 359 
observed effects and if indeed the combination of the two interventions can provide an 360 
additional benefit to the older adult. 361 
Due to the range of compounds in the multi-nutrient supplementation it is not possible to 362 
ascribe the effects to any single factor, and the present results further support the use of a 363 
combination of dietary factors in aging 
(4, 45)
. Unfortunately, due to methodological issues we 364 
were unable to monitor changes in serum Hcy levels over the study and so cannot identify the 365 
potential role of folic acid and vitamin B12 in the treatment effects. However, a major 366 
unifying factor in the multi-nutrient intervention is DHA, and the supplementation increased 367 
circulating DHA and EPA levels. To identify the potential contribution of DHA to the 368 
treatment effects correlations between changes in DHA and changes in outcome measures 369 
were performed. The increases in DHA levels over the study were in direct relation with 370 
improvements in verbal memory, suggesting increasing DHA was an important contributor to 371 
the treatment effects on this outcome. At baseline, significant relationships were seen with 372 
DHA and DT gait speed, although no other measures of mobility or cognition. Previous 373 
observations suggest circulating DHA levels correlate with gait and mobility outcomes 
(4, 46)
 , 374 
although erythrocyte DHA and EPA was not shown to be associated with a slower decline in 375 
gait speed over three years in a fully adjusted model 
(47)
. The results from the present study do 376 
provide some further support for DHA status as a potential blood biomarker for monitoring 377 
physical performance in aging, although further work is needed to establish this link more 378 
clearly.  379 
The strengths of this study are that it was randomised, placebo controlled semi-blinded 380 
design, with high retention rate, thereby increasing the reliability of the data. The study used 381 
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a range of detailed and sensitive mobility and cognitive tests to assess treatment effects. It is 382 
important in this type of study to monitor participant’s dietary intake and physical activity; 383 
these were assessed by diet diary and FFQ, and CHAMPS questionnaire, respectively. This 384 
meant it could be confirmed that the participants diet and physical activity outside of the 385 
interventions remained consistent. The only notable, although not statistically significant, 386 
change in diet was a decrease in fat intake across all four groups; however we have no reason 387 
to believe this decrease across the groups would have influenced the results of the analysis. 388 
Furthermore, the trial design was reviewed and made publicly available on a clinical trials 389 
registry and was subject to peer review during the protocol publication process. Additionally, 390 
blood fatty acid levels were taken at the start and end of the study, to monitor absorption and 391 
incorporation of the omega-3 PUFAs. Limitations were the low recruitment, and high 392 
functional ability of the participants. A further limitation was that ApoE genotype was not 393 
assessed, as this may affect participant’s response to the supplementation (48), and is 394 
associated with gait speed decline in aging 
(49)
.  395 
 396 
Conclusions 397 
Overall, these results suggest that the multi-nutrient supplement produces similar 398 
improvements in verbal memory and executive function to aerobic exercise, offering the 399 
intriguing prospect that supplementation may be able to mitigate some of the effects of low 400 
physical activity on cognitive function in the elderly. These improvements are clinically 401 
relevant and were identified in able female adults. Treatment effects were not identified in the 402 
primary outcome, nonetheless the improvements in verbal memory and executive function 403 
does provide some promising insight into the benefits of dietary supplementation and 404 
exercise for the promotion of healthy ageing. The study identified for the first time 405 
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relationships between DHA and DT ability. Further work should seek to explore the effects 406 
of the supplement on participants who may be most likely to respond, i.e. those with low 407 
DHA and high Hcy levels, and also explore supplementation for a longer period, or in a more 408 
frail population. 409 
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 563 
Figure 1 Participant flow through study  564 
 565 
Figure 2 Effects of multi-nutrient supplement and exercise on the primary outcome of 566 
habitual gait speed. There were no significant effects for any intervention on changes in gait 567 
speed. 568 
 569 
Figure 3 Effects of multi-nutrient supplement and exercise by general linear model on Rey’s 570 
auditory verbal learning test. Significant effects for multi-nutrient supplement (p = 0.008) 571 
placebo supplement and exercise (p = 0.008) and combination of multinutrient and exercise 572 
(p < 0.001). See text for further detail. 573 
* Indicates a significant effect of the intervention on changes in verbal memory versus 574 
placebo.  575 
 576 
Figure 4 Effects of multi-nutrient supplement and exercise by general linear model on 577 
executive function. Significant effects for multi-nutrient supplement (p = 0.007) placebo 578 
supplement and exercise (p = 0.006) and combination of multinutrient and exercise (p < 579 
0.005). See text for further detail. 580 
* Indicates a significant effect of the intervention on changes in executive function versus 581 
placebo.  582 
 583 
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Figure 5 Scatter plot for changes in DHA and change in verbal memory for MS and P groups, 584 
r(18) = 0.66, p = 0.001. 585 
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Table 1 Participant characteristics at baseline.   
Parameter PL 
(N = 12) 
PL + EX 
(N = 12) 
MS 
(N = 13) 
MS + EX 
(N = 14) 
Age (years) 67 (4) 67 (4) 69 (4) 68 (5) 
Height (m) 1.63 (0.1) 1.64 (0.1) 1.62 (0.1) 1.61 (0.1) 
Weight (kg) 69.5 (14.9)* 77.1 (33)* 75.6 (17.4)* 68.6 (11.1)* 
BMI (kg/m
2
) 26.8 (5.2)* 27.8 (12.0)* 27.4 (5.3)* 28.6 (5.9)* 
Comorbidities  Hypertension (2) 
Hypercholesterolemia (1) 
Osteoarthritis  (2) 
Hypertension (3) 
Osteoarthritis (1) 
Hypertension (2) 
Hypercholesterolemia (1) 
Osteoporosis (1) 
Hypertension (3) 
Hypercholesterolemia (2) 
Diabetes (1) 
Osteoarthritis (2) 
NART Score 36 (8) 36 (5) 37 (5) 36 (7) 
MMSE score 30 (1)* 30 (0)* 30 (1)* 30 (2)* 
Hand Grip 
Strength (kg) 
20.5 (3.4) 21.0 (5.9) 19.3 (5.4) 19.0 (4.0) 
PASE Score 114 (97)* 113 (30)* 111 (73)* 100 (55)* 
25 
 
*Indicates value is the median (IQR), otherwise means (SD) presented. 
Abbreviations: Mini Mental Sate Exam, MMSE; National Adult Reading Test, NART; Physical Activity Scale in the Elderly, PASE
26 
 
* Indicates a significant change versus baseline, assessed using paired T-test or Wilcoxon signed-rank test where appropriate  
a
 N = 10 and 
b
 N = 10 for whole-blood fatty acid value 
Table 2: Participant compliance 
   Parameter PL 
(N = 12)
a 
PL+EX  
(N = 12) 
MS  
(N = 13)
b 
MS+EX  
(N = 14) 
 Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks 
Fatty acid levels (% total fatty acids) 
ARA 6.6 (1.2) 6.3 (1.5) 6.7 (2.0) 6.9 (1.1) 7.1 (3.4) 5.1 (1.2)* 6.9 (2.0) 5.1 (1.4)* 
EPA 0.4 (0.2) 0.4 (0.2) 0.4 (0.2) 0.4 (0.3) 0.3 (0.1) 0.9 (0.2)* 0.4 (0.2) 0.8 (0.4)* 
DHA 1.7 (0.4) 1.6 (0.4) 1.7 (0.6) 1.5 (0.4) 1.8 (0.6) 2.3 (0.5)* 1.5 (0.4) 2.1 (0.6)* 
Dietary intake per day 
Kcal 1869 (440) 1772 (518) 1530 (386) 1507 (310) 1642 (464) 1489 (439) 1738 (293 1565 (339) 
Carbohydrate (g) 190 (41) 180 (51) 156 (45) 154 (43) 175 (49) 168 (51) 175 (33) 164 (39) 
Protein 
(g/kg bodyweight) 
1.12 (0.38) 1.11 (0.34) 0.91 (0.40) 0.91 (0.36) 1.00 (0.26) 0.93 (0.28) 1.09 (0.19)  0.96 (0.21) 
Fat (g) 84 (25) 76 (31) 68 (23) 62 (10) 67 (27) 63 (25) 73 (19) 66 (23) 
Physical activity  
CHAMPs (kcal) 3619 (2159) 3390 (1686) 3454 (2009) 4011(2622)* 4314 (2328) 3945(2098) 3289 (1537) 3650 (1523)* 
27 
 
Table 3 Secondary outcome measures displayed as mean (SD) 
 
 Parameter PL  
(N = 12) 
PL + EX  
(N = 12) 
MS  
(N = 13) 
MS + EX  
(N =14) 
 Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks 
Mobility  
Fast Walking 
Speed (m/s) 
1.8 (0.3) 1.7 (0.2) 1.6 (0.3) 1.6 (0.2) 1.6 (0.2) 1.6 (0.2) 1.7 (0.2) 1.7 (0.2) 
DT Gait Speed 
(m/s) 
0.9 (0.3) 1.0 (0.2) 1.1 (0.2) 1.1 (0.2) 1.0 (0.3) 1.0 (0.3) 1.2 (0.3) 1.2 (0.3) 
Five Times Sit 
to Stand (s) 
11.8 (2.1) 11.7 (2.3) 13.9 (3.9) 13.0 (3.0) 11.9 (2.1) 11.9 (2.2) 13.9 (3.9) 12.3 (2.6) 
Cognition  
Verbal 
Memory (%) 
58 (11) 54 (16) 61 (14) 67 (13) 54 (13.0) 60 (13) 58 (13) 67 (15) 
Spatial 
Memory (%) 
75 (7) 75 (6) 77 (5) 75 (6) 77 (7) 73 (7) 75 (7) 72 (10) 
Executive 
Function 
(Correct 
Connections) 
80 (18) 75 (19) 68 (21) 76 (23) 60 (15) 67 (21) 68 (18) 75 (15) 
Interference 
Control (ms) 
159 (90) 152 (77) 149 (96) 118 (104) 210 (106) 189 (104) 205 (198) 169 (148) 
SF-36 Questionnaire  
Physical 
Function 
79 (24) 78 (26) 75 (21) 79 (19) 82 (15) 83 (16) 75 (26) 77 (22) 
Bodily Pain 75 (24) 73 (25) 75 (22) 80 (13) 74 (19) 77 (17) 66 (21) 66 (16) 
Emotional 
Wellbeing 
75 (23) 72 (24) 82 (17) 80 (14) 79 (14) 79 (13) 69 (18) 74 (17) 
Energy 
/ Fatigue 
57 (25) 55 (25) 65 (26) 67 (24) 62 (22) 63 (19) 58 (25) 58 (24) 
General 
Health  
66 (23) 70 (23) 75 (18) 76 (18) 66 (16) 66 (19) 62 (24) 62 (24) 
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Supplementary Table 1 Fatty Acid Composition of Placebo Capsules. 
Fatty Acid Profile % Fatty Acid Methyl Ester Milligram triglyceride  
per Capsule 
14:0 Myristic 0.4 3.3 
16:0 Palmitic 7.3 67.8 
16:1 Hexadecenoic 0.5 4.2 
16:3 Heptadecatrienoic 0.1 0.5 
16:4 Hexadecatetraenoic 0.1 0.8 
17:0 Heptadecanoic 0.1 0.5 
18:0 Stearic 6.6 60.3 
18:1 (n-9) Oleic 72.4 656.5 
18:1 (n-7) CIS-vaccenic 0.8 6.8 
18:2 (n-7) Linoleic 8.2 74.1 
18:3 (n-3) Alpha-linoleic 0.1 1.1 
18:4 (n-3) Octadecatetraenoic 0.1 1.2 
20:0 Icosanoic 0.3 2.7 
20:1 Icosenoic 0.3 3.0 
20:4 (n-6) Arachidonic 0.0 0.4 
20:5 (n-3) Icosapentaenoic 0.8 6.8 
22:0 Docosanoic 0.9 7.6 
22:1 (n-11) Cetoleic 0.1 0.8 
22:5 (n-3) Docosapentaenoic 0.1 0.7 
24:0 Tetracosanoic 0.3 2.5 
22:6 (n-3) Docosahexaenoic 0.5 4.3 
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Supplementary Table 2 Correlation matrix plotting serum homocysteine against 
primary and secondary outcome measures. 
Outcome Measure  Homocysteine Correlation  
Habitual Gait Speed (m/s) R=0.190 (p=0.197) 
Fast Walking Speed (m/s) R=0.256 (p=0.079) 
Dual Task Gait Speed (m/s)   R=-0.005 (p=0.975) 
DTE on Gait Speed (%)   R=-0.209 (p=0.155) 
Dual Task Variability (%) R=0.040 (p=0.788) 
FTSTS (s) R= 
Verbal Memory (%) R=-0.093 (p=0.528) 
SWM (%) R=-0.194 (p=0.187) 
EF (number of correct connections) R=0.218 (p=0.136) 
Interference control (ms) R=-0.158 (p=0.283) 
Physical Function (SF-36 score) R=0.083 (p=0.591) 
Emotional Wellbeing (SF-36 score) R=-0.289 (p=0.057) 
Energy/ Fatigue (SF-36 score) R=0.042 (p=0.787) 
Bodily Pain (SF-36 score) R=-0.050 (p=0.749) 
General Health Perceptions (SF-36 score) R=-0.138 (p=0.373) 
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